MCID: GLM007
MIFTS: 61

Glomerulonephritis

Categories: Rare diseases, Nephrological diseases

Aliases & Classifications for Glomerulonephritis

MalaCards integrated aliases for Glomerulonephritis:

Name: Glomerulonephritis 37 12 72 49 51 41 14 69
Bright's Disease 49

Classifications:



External Ids:

Disease Ontology 12 DOID:2921
ICD10 32 N05 N08
MeSH 41 D005921
NCIt 46 C26784
SNOMED-CT 64 197648001 36171008
UMLS 69 C0017658

Summaries for Glomerulonephritis

NIH Rare Diseases : 49 Glomerulonephritis is a type of kidney disease in which there is inflammation of the glomeruli, the tiny filters that remove excess waste and fluids from the blood. It may be acute or chronic (coming on gradually), and may occur on its own (primary) or be caused by another condition (secondary). Signs and symptoms may depend on the type and cause of the condition and may include blood in the urine; foamy urine; swelling of the face, eyes, or other body parts; abdominal pain; high blood pressure; fatigue; and/or other symptoms. If the condition is severe or prolonged, the kidneys can become damaged. It may be caused by a variety of infections and diseases, and sometimes the cause is unknown. Treatment depends on the cause, type and severity of the condition. Last updated: 7/17/2012

MalaCards based summary : Glomerulonephritis, also known as bright's disease, is related to rapidly progressive glomerulonephritis and immune-complex glomerulonephritis. An important gene associated with Glomerulonephritis is CFHR5 (Complement Factor H Related 5), and among its related pathways/superpathways are Innate Immune System and Selenium Micronutrient Network. The drugs Angiotensin II and Losartan have been mentioned in the context of this disorder. Affiliated tissues include Kidney, kidney and kidney, and related phenotypes are hematopoietic system and homeostasis/metabolism

Disease Ontology : 12 A nephritis that causes inflammation of the glomeruli located in kidney.

Wikipedia : 72 Glomerulonephritis (GN), also known as glomerular nephritis, is a term used to refer to several kidney... more...

Related Diseases for Glomerulonephritis

Diseases in the Glomerulonephritis family:

Subacute Glomerulonephritis

Diseases related to Glomerulonephritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 644)
# Related Disease Score Top Affiliating Genes
1 rapidly progressive glomerulonephritis 34.1 CD79A MPO PRTN3
2 immune-complex glomerulonephritis 33.9 C4B CFI MPO
3 exudative glomerulonephritis 33.5 CD40LG CD79A
4 proliferative glomerulonephritis 33.4 C3 CCL2 CD79A CFH CR1
5 acute proliferative glomerulonephritis 33.4 CCL2 CD40LG CD79A COL4A3 MPO
6 complement factor h deficiency 33.4 CFH CFI
7 diffuse glomerulonephritis 33.3 ALB CD40LG CD79A
8 goodpasture syndrome 33.2 CD79A COL4A3 COL4A5 MPO
9 dense deposit disease 33.2 C3 CFH CFHR5
10 membranoproliferative glomerulonephritis 33.1 ALB C3 C4A CD79A CFH CFHR5
11 c3 glomerulopathy 33.1 C3 CFHR5
12 membranous nephropathy 32.8 ALB CD79A LRP2 NPHS1
13 iga glomerulonephritis 32.6 ALB C4A CCL2 CD40LG CD79A NPHS1
14 alport syndrome, x-linked 32.4 CD79A COL4A3 COL4A5
15 henoch-schoenlein purpura 31.9 C3 CD40LG CD79A MPO
16 lipoid nephrosis 31.8 ALB CCL2 CD79A NPHS1
17 hemolytic-uremic syndrome 30.7 C3 CFH CFHR5 CFI
18 focal segmental glomerulosclerosis 30.6 ALB COL4A3 COL4A5 NPHS1
19 vasculitis 30.4 CCL2 CD40LG CD79A MPO PRTN3
20 churg-strauss syndrome 30.4 CD40LG MPO PRTN3
21 lupus erythematosus 30.2 C1QC C1S C3 C4A C4B CD40LG
22 subacute bacterial endocarditis 30.1 CD40LG CD79A
23 complement factor i deficiency 30.1 C3 C4B CFI CR1
24 rheumatoid arthritis 30.0 CCL2 CD40LG CD79A CSF1 PRTN3
25 systemic lupus erythematosus 30.0 ALB C1QC C1S C3 C4A C4B
26 anemia, autoimmune hemolytic 30.0 C3 CD40LG CD79A
27 c1q nephropathy 30.0 CD40LG CD79A
28 lyme disease 30.0 C3 CD40LG CFH
29 pulmonary hemosiderosis 29.8 CD40LG CD79A MPO PRTN3
30 kidney disease 29.8 ALB COL4A3 COL4A5 NPHS1
31 primary biliary cirrhosis 29.8 ALB CD40LG CD79A PRTN3
32 hereditary angioedema 29.8 C1S C4A C4B
33 immunoglobulin alpha deficiency 29.8 C4A CD40LG CD79A
34 meningitis 29.7 ALB CCL2 CD40LG
35 macular degeneration, age-related, 1 29.6 C3 CCL2 CFH CFHR5 CFI
36 schistosomiasis 29.5 ALB CD40LG CD79A
37 end stage renal failure 29.5 ALB CD79A COL4A5 NPHS1
38 tolosa-hunt syndrome 29.5 CD40LG PRTN3
39 bronchopneumonia 29.4 CD40LG CD79A MPO
40 immunoglobulin a deficiency 1 29.4 CD40LG CD79A
41 cogan syndrome 29.4 CD40LG CD79A COL4A3
42 congenital syphilis 29.4 CD40LG CD79A
43 cholangitis 29.4 ALB CD40LG PRTN3
44 myeloma, multiple 29.3 ALB CD40LG CD79A
45 chronic kidney failure 29.3 ALB CD79A COL4A5 NPHS1
46 guillain-barre syndrome 29.3 ALB CD40LG CD79A
47 acquired immunodeficiency syndrome 29.2 ALB CD40LG CD79A
48 bronchitis 29.1 ALB CD40LG CD79A MPO
49 mesangial proliferative glomerulonephritis 12.3
50 fibrillary glomerulonephritis 12.3

Graphical network of the top 20 diseases related to Glomerulonephritis:



Diseases related to Glomerulonephritis

Symptoms & Phenotypes for Glomerulonephritis

MGI Mouse Phenotypes related to Glomerulonephritis:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.03 C3 C4B CD40LG CD79A CFH CFI
2 homeostasis/metabolism MP:0005376 9.97 ALB C3 C4B CD40LG CD79A CFH
3 immune system MP:0005387 9.73 C4B CCL2 CD40LG CD79A CFH COL4A3
4 renal/urinary system MP:0005367 9.36 ALB C3 C4B CD40LG CD79A CFH

Drugs & Therapeutics for Glomerulonephritis

Drugs for Glomerulonephritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 263)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Angiotensin II Approved, Investigational Phase 4,Phase 2,Phase 3 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
2
Losartan Approved Phase 4,Phase 3,Phase 2 114798-26-4 3961
3
Cilnidipine Approved, Investigational Phase 4 132203-70-4 5282138
4
Enalapril Approved, Vet_approved Phase 4,Phase 2 75847-73-3 40466924 5362032
5
Enalaprilat Approved Phase 4,Phase 2 76420-72-9 6917719
6
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
7
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
8
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
9
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 22916-47-8 4189
10
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 53-03-2 5865
11
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 104987-11-3 445643 439492
12
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 128794-94-5 5281078
13
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 24280-93-1 446541
14
Triamcinolone Approved, Vet_approved Phase 4,Phase 1 124-94-7 31307
15
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 50-18-0, 6055-19-2 2907
16
Ramipril Approved Phase 4,Phase 3 87333-19-5 5362129
17
Probucol Approved, Investigational Phase 4 23288-49-5 4912
18
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
19
Hydroxychloroquine Approved Phase 4 118-42-3 3652
20
Azathioprine Approved Phase 4,Phase 3,Phase 2,Phase 1 446-86-6 2265
21
Bortezomib Approved, Investigational Phase 4 179324-69-7 387447 93860
22
Benzocaine Approved, Investigational Phase 4,Phase 3 1994-09-7, 94-09-7 2337
23
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
24
Basiliximab Approved, Investigational Phase 4,Phase 2 179045-86-4, 152923-56-3
25
Artesunate Approved, Investigational Phase 4 88495-63-0 5464098 6917864
26
Calcitriol Approved, Nutraceutical Phase 4,Phase 2 32222-06-3 5280453 134070
27 tannic acid Approved, Nutraceutical Phase 4,Phase 3
28
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 1406-16-2
29
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3 50-14-6 5280793
30
N,N-dimethylarginine Experimental Phase 4 30315-93-6 123831
31
Candesartan Experimental Phase 4 139481-59-7 2541
32 Dexchlorpheniramine Experimental, Investigational Phase 4 25523-97-1
33 Angiotensin II Type 1 Receptor Blockers Phase 4,Phase 2,Phase 3
34 Angiotensin Receptor Antagonists Phase 4,Phase 2,Phase 3
35 Angiotensinogen Phase 4,Phase 2,Phase 3
36 Anti-Arrhythmia Agents Phase 4,Phase 3,Phase 2
37 Antihypertensive Agents Phase 4,Phase 3,Phase 2
38 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
39 Bone Density Conservation Agents Phase 4,Phase 2,Phase 3
40 Calcium, Dietary Phase 4,Phase 2,Phase 3
41 Immunoglobulin A Phase 4,Phase 2,Phase 3,Phase 1
42 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
43 Micronutrients Phase 4,Phase 3,Phase 2
44 Trace Elements Phase 4,Phase 3,Phase 2
45 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2
46 Vitamins Phase 4,Phase 3,Phase 2
47 Mitogens Phase 4,Phase 2
48 Adrenergic Agents Phase 4,Phase 3
49 Adrenergic alpha-Antagonists Phase 4
50 Adrenergic Antagonists Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 339)

# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis Unknown status NCT02063100 Phase 4 Shenyankangfu tablets;Losartan potassium 50mg;Shenyankangfu tablets and Losartan potassium 50mg;Shenyankangfu tablets and Losartan potassium 100mg;Losartan potassium 100mg
2 Calcitriol in the Treatment of Immunoglobulin A Nephropathy Unknown status NCT00862693 Phase 4 Calcitriol
3 A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy Unknown status NCT01184599 Phase 4 aliskiren
4 CCB Safety Study in Treatment of Hypertension of ADPKD Unknown status NCT00541853 Phase 4 Candesartan;Candesartan and Cilnidipine;Candesartan plus non-CCB agents
5 Rituximab in Recurrent IgA Nephropathy Unknown status NCT02571842 Phase 4 Intravenous Rituximab;ACEI/ARB and corticosteroids
6 Inhibitors of Angiotensin II in Proteinuric Mesangioproliferative Glomerulonephritis Completed NCT01115426 Phase 4 Ramipril or losartan
7 HSP-glomerulonephritis Trial: MP vs CyA Completed NCT00425724 Phase 4 Methylprednisolone pulses plus prednisone versus Cyclosporine A
8 Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis Completed NCT01206569 Phase 4 Long-acting tacrolimus (Advagraf, Astellas Pharma)
9 Calcitriol in the Treatment of Immunoglobulin A (IgA) Nephropathy Completed NCT00319761 Phase 4 Calcitriol
10 A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy Completed NCT00426348 Phase 4 Valsartan;Probucol;Placebo
11 Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy: a Self- Controlled Study Completed NCT02351752 Phase 4 Hydroxychloroquine Sulfate
12 Mycophenolate Mofetil for IgA Nephropathy Completed NCT00863252 Phase 4 mycophenolate mofetil;angiotensin blockade
13 Comparing the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis Completed NCT00371319 Phase 4 tacrolimus;mycophenolate mofetil
14 Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects Completed NCT02585804 Phase 4 Dapagliflozin
15 A Study to Evaluate the Effect of Tacrolimus and Corticosteroid Combination Therapy in Patients With Minimal Change Nephrotic Syndrome Completed NCT01763580 Phase 4 Tacrolimus;Prednisolone
16 The Effects of Angiotensin II Receptor Blockade on Kidney Function and Scarring After Liver Transplant Completed NCT00275639 Phase 4 Cozaar
17 Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis Completed NCT00125307 Phase 4 tacrolimus
18 Aliskiren for Proteinuric IgAN Despite Angiotensin Blockade Completed NCT00922311 Phase 4 Aliskiren
19 "Steroids and Azathioprine Versus Steroids Alone in IgAN" Completed NCT00755859 Phase 4 steroids plus azathioprine;steroids
20 Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy Completed NCT00498368 Phase 4 Intravenous Rituximab;ACE/ARB
21 To Compare the Efficacy and Safety of Tripterygium Wilfordii (TW) Versus Valsartan in the Membranous Nephropathy (MN) Completed NCT00518219 Phase 4 TW
22 Low-dose Combination of Mycophenolate Mofetil (MMF) and Tacrolimus (Tac) for Refractory Lupus Nephritis Completed NCT01203709 Phase 4 low dose combination of MMF and Tac
23 Pilot Study of Velcade® in IgA Nephropathy Completed NCT01103778 Phase 4 Bortezomib (Velcade®)
24 Inhibition of the Renin Angiotensin System Plus Corticosteroids for the Treatment of Proteinuria in IGA Nephropathy Completed NCT00367562 Phase 4 ENALAPRIL VALSARTAN METHYLPREDNISONE
25 Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients Completed NCT01386554 Phase 4 Repository Corticotropin Injection;Placebo
26 Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH Completed NCT01155141 Phase 4 H.P. Acthar Gel
27 Comparison of Low Dose Versus High Dose Cyclophosphamide as Induction Therapy in the Treatment of Lupus Nephritis Completed NCT02645565 Phase 4 Cyclophosphamide;Azathioprine;Methylprednisolone
28 Tacrolimus Combined With Entecavir on HBV Associated Glomerulonephritis(HBV-GN) Recruiting NCT03062813 Phase 4 Tacrolimus &entecavir;placebo & entecavir
29 ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis Recruiting NCT01926054 Phase 4 Acthar gel
30 Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy Recruiting NCT02765594 Phase 4 Hydroxychloroquine Sulfate;Valsartan
31 Adrenocorticotropic Hormone in Membranous Nephropathy Recruiting NCT03025828 Phase 4 ACTHar
32 Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid in Advanced IgA Nephropathy Recruiting NCT02981212 Phase 4 Mycophenolate Mofetil;ACE inhibitor;Corticosteroid;ARB
33 Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous Nephropathy Recruiting NCT03170323 Phase 4 Mycophenolate Mofetil;Cyclosporins
34 Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy Recruiting NCT02231125 Phase 4 Losartan;Abelmoschus manihot
35 Efficacy and Safety of Tacrolimus Versus Mycophenolate in Lupus Nephritis Recruiting NCT02630628 Phase 4 Tacrolimus;Mycophenolate mofetil
36 ACTHar in the Treatment of Lupus Nephritis Recruiting NCT02226341 Phase 4 CellCept;ACTHar gel;ACTHar gel
37 Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic FSGS Recruiting NCT02633046 Phase 4 Acthar 80 U 2x/week;Acthar 80 U 3x/week
38 Mycophenolate Mofetil and Tacrolimus Versus Tacrolimus for the Treatment of Idiopathic Membranous Glomerulonephritis (IMG) Active, not recruiting NCT00843856 Phase 4 tacrolimus;tacrolimus and mycophenolate mofetil
39 Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment Active, not recruiting NCT02523768 Phase 4 ATG-F;Simulect
40 Extended Follow-up of Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy Active, not recruiting NCT03218852 Phase 4 prednisone and cyclophosphamide;prednisone alone
41 Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy Active, not recruiting NCT01758120 Phase 4 prednisone plus cyclophosphamide;Prednisone alone
42 Immunoadsorption in Anti-GBM Glomerulonephritis. Not yet recruiting NCT02765789 Phase 4
43 Efficacy and Safety of Artesunate Plus Standard of Care in Active Lupus Nephritis Not yet recruiting NCT03214731 Phase 4 Artesunate
44 Effect of Immunosuppression in IgA Nephropathy Not yet recruiting NCT03468972 Phase 4 Immunosuppressive treatment
45 Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease Terminated NCT01129557 Phase 4 Aliskiren;Valsartan
46 A Study to Evaluate the Efficacy and Safety of Tacrolimus With Steroid in Korean Lupus Nephritis Patients Terminated NCT01316133 Phase 4 tacrolimus
47 The Efficacy and Safety of Calcitriol for the Treatment of Lupus Nephritis and Persistent Proteinuria Withdrawn NCT00508898 Phase 4 Calcitriol;Multivitamin
48 Acthar on Proteinuria in IgA Nephropathy Patients Withdrawn NCT02382523 Phase 4 Acthar 80 unit injection
49 Velcade for Proliferative Lupus Nephritis Withdrawn NCT01169857 Phase 4 Velcade
50 Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy Unknown status NCT01282073 Phase 3 Mycophenolate mofetil, low dose steroid;Cyclosporin, low dose steroid

Search NIH Clinical Center for Glomerulonephritis

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Glomerulonephritis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Glomerulonephritis:
Mesenchymal stromal cells for glomerulonephritis
Embryonic/Adult Cultured Cells Related to Glomerulonephritis:
Bone marrow-derived mesenchymal stromal cells PMIDs: 22172807

Cochrane evidence based reviews: glomerulonephritis

Genetic Tests for Glomerulonephritis

Anatomical Context for Glomerulonephritis

The Foundational Model of Anatomy Ontology organs/tissues related to Glomerulonephritis:

18
Kidney

MalaCards organs/tissues related to Glomerulonephritis:

38
Kidney, Neutrophil, Liver, T Cells, Monocytes, Bone, Eye
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Glomerulonephritis:
# Tissue Anatomical CompartmentCell Relevance
1 Kidney Glomerulus Affected by disease

Publications for Glomerulonephritis

Articles related to Glomerulonephritis:

(show top 50) (show all 3981)
# Title Authors Year
1
Levamisole Induced Pauci Immune Focal Necrotizing and Crescentic Glomerulonephritis. ( 29292489 )
2018
2
C3 glomerulonephritis secondary to mutations in factors H and I: rapid recurrence in deceased donor kidney transplant effectively treated with eculizumab. ( 29370420 )
2018
3
C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. ( 29310824 )
2018
4
Posterior Reversible Encephalopathy Syndrome Secondary to Acute PostStreptococcal Glomerulonephritis in a 12-year-old Girl. ( 29290203 )
2018
5
Tuberculosis and pauci-immune crescentic glomerulonephritis. ( 29437730 )
2018
6
Ciliary metaplasia in a patient with antineutrophil cytoplasmic autoantibody-associated pauci-immune glomerulonephritis. ( 29295613 )
2018
7
Rapidly progressive glomerulonephritis caused by overlap syndrome of IgG4-related tubulointerstitial nephritis and myeloperoxidase-antineutrophil cytoplasmic antibody-associated necrotising glomerulonephritis. ( 29352845 )
2018
8
18F-FDG PET/CT Imaging of Necrotizing Crescentic Glomerulonephritis With Anti-Glomerular Basement Membrane Disease. ( 29293138 )
2018
9
Quantitative characterization of glomerular fibrosis with magnetic resonance imaging: a feasibility study in a rat glomerulonephritis model. ( 29357425 )
2018
10
Hypocomplementemic Urticarial Vasculitis Syndrome With Crescentic Glomerulonephritis. ( 29406049 )
2018
11
Prospects for Precision Medicine in Glomerulonephritis Treatment. ( 29449955 )
2018
12
Membranous glomerulonephritis with an LMNA mutation. ( 29349732 )
2018
13
Rituximab therapy for hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis. ( 29445495 )
2018
14
Membranoproliferative glomerulonephritis with unusual deposits of parallel arrangement striated structure: a new pathological entity?a8c. ( 29057733 )
2018
15
Membranoproliferative glomerulonephritis and interstitial nephritis in the setting of Epstein-Barr virus-related hemophagocytic syndromea8c. ( 29350173 )
2018
16
The atypical chemokine receptor 2 limits renal inflammation and fibrosis in murine progressive immune complex glomerulonephritis. ( 29395335 )
2018
17
Urine epidermal growth factor, monocyte chemoattractant protein-1 or their ratio as predictors of complete remission in primary glomerulonephritis. ( 29414320 )
2018
18
Is there a correlation between kidney shear wave velocity measured with VTQ and histological parameters in patients with chronic glomerulonephritis? A pilot study. ( 29400364 )
2018
19
Parathyroid Hormone-Related Protein Contributes to Early Healing of Habu Snake Venom-Induced Glomerulonephritis in Mice. ( 29353060 )
2018
20
Quantification of cancer risk in glomerulonephritis. ( 29394927 )
2018
21
Posterior reversible encephalopathy syndrome secondary to asymptomatic poststreptococcal glomerulonephritis in a child with sickle cell anemia: a case report. ( 29386039 )
2018
22
DNAJB9 Is a Specific Immunohistochemical Marker for Fibrillary Glomerulonephritis. ( 29340314 )
2018
23
Unusual presentation of secondary syphilis: membranoproliferative glomerulonephritis andmuco-cutaneous lesions. ( 28950764 )
2017
24
Membranoproliferative Glomerulonephritis Associated with a Human Immunodeficiency Virus Infection. ( 28761237 )
2017
25
A case report of proliferative glomerulonephritis with monoclonal immunoglobulin M-kappa deposits without associated lymphoproliferative disorder or detectable paraproteinemia. ( 29230710 )
2017
26
Hepatitis C virus-associated cryoglobulinemia with membrano-proliferative glomerulonephritis treated with prednisolone and interferon: A case report. ( 28810602 )
2017
27
(5R)-5-hydroxytriptolide ameliorates anti-glomerular basement membrane glomerulonephritis in NZW mice by regulating FcI^ receptor signaling. ( 28880016 )
2017
28
Fibrillary glomerulonephritis presenting as crescentic glomerulonephritis. ( 28356674 )
2017
29
Primary SjAPgren's syndrome complicated by anti-neutrophil cytoplasmic antibody-mediated crescentic glomerulonephritis. ( 28937084 )
2017
30
Panitumumab-Induced Immune Complex Glomerulonephritis. ( 27765383 )
2017
31
MPO-C-ANCA-associated necrotising and crescentic glomerulonephritis. ( 28491331 )
2017
32
Antineutrophil cytoplasmic antibody-positive pauci-immune glomerulonephritis associated with mantle cell lymphoma. ( 29043141 )
2017
33
Paraneoplastic pauci-immune glomerulonephritis in a patient with lung carcinoma. ( 28946967 )
2017
34
Cardiac status in children with acute poststreptococcal glomerulonephritis. ( 28748885 )
2017
35
ANCA-Positive pauci-immune crescentic glomerulonephritis in a patient with systemic lupus erythematosus. ( 29319773 )
2017
36
The Small Tellurium Compound AS101 Ameliorates Rat Crescentic Glomerulonephritis: Association with Inhibition of Macrophage Caspase-1 Activity via Very Late Antigen-4 Inactivation. ( 28326083 )
2017
37
Clinical features and pathogenesis of membranoproliferative glomerulonephritis: a nationwide analysis of the Japan renal biopsy registry from 2007 to 2015. ( 29214407 )
2017
38
Interstitial Immunostaining and Renal Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis. ( 28881339 )
2017
39
Pre- and Posttransplant Refractory Idiopathic Membranous Glomerulonephritis: The Forgotten Potential Culprit. ( 28847264 )
2017
40
Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies. ( 28573137 )
2017
41
Genetic and pharmacological inhibition of microRNA-92a maintains podocyte cell cycle quiescence and limits crescentic glomerulonephritis. ( 29184126 )
2017
42
Membranoproliferative glomerulonephritis associated with Rosai-Dorfman disease. ( 29043148 )
2017
43
A case report of paraproteinemia-associated pauci-immune glomerulonephritis - a new form of monoclonal gammopathy of renal significance? ( 29043147 )
2017
44
ANCA-associated pauci-immune glomerulonephritis in a patient with bacterial endocarditis: a challenging clinical dilemma. ( 29043145 )
2017
45
Fibrillary Glomerulonephritis in Primary Sjogren's Syndrome: A Rare Cause of Renal Failure. ( 29196420 )
2017
46
Glomerular disease: Crescentic glomerulonephritis: beyond the immune system. ( 28298632 )
2017
47
Unusual Proliferative Glomerulonephritis in a Patient Diagnosed to Have Hypoparathyroidism, Sensorineural Deafness, and Renal Dysplasia (HDR) Syndrome with a Novel Mutation in the GATA3 Gene. ( 28566604 )
2017
48
Complement activation in pauci-immune necrotizing and crescentic glomerulonephritis: results of a proteomic analysis. ( 28391334 )
2017
49
Clinical and histological features of patients with membranoproliferative glomerulonephritis classified by immunofluorescence findings. ( 29319772 )
2017
50
Antineutrophil Cytoplasmic Antibody-Associated Rapid Progressive Glomerulonephritis after Pembrolizumab Treatment in Thymic Epithelial Tumor: A Case Report. ( 28342816 )
2017

Variations for Glomerulonephritis

Copy number variations for Glomerulonephritis from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 21052 1 156500000 165500000 Copy number FCGR3 Glomerulonephritis
2 21055 1 156500000 165500000 Loss FCGR3B Glomerulonephritis
3 21056 1 156500000 165500000 Low copy number FCGR3B Glomerulonephritis

Expression for Glomerulonephritis

Search GEO for disease gene expression data for Glomerulonephritis.

Pathways for Glomerulonephritis

Pathways related to Glomerulonephritis according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.84 C1QC C1S C3 C4A C4B CCL2
2
Show member pathways
12.21 ALB CCL2 CSF1 LRP2 MPO
3
Show member pathways
12.02 C1QC C1S C3 C4A C4B CFH
4 11.9 C1QC C1S C3 C4A C4B CFH
5
Show member pathways
11.89 C1QC C1S C3 C4A C4B CFH
6 11.7 CCL2 COL4A3 COL4A5
7
Show member pathways
11.68 C1QC C1S C3 C4A C4B CFH
8 11.65 C1QC C1S C3 C4A C4B
9 11.63 COL4A3 COL4A5 CR1 NPHS1
10 11.36 CCL2 CD40LG CR1
11 10.92 C1QC C1S C3 C4A C4B CFH
12 10.81 CCL2 CD40LG COL4A3 COL4A5 CSF1
13 10.81 CCL2 CSF1 MPO

GO Terms for Glomerulonephritis

Cellular components related to Glomerulonephritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.93 ALB C1QC C3 C4A C4B CCL2
2 endoplasmic reticulum lumen GO:0005788 9.8 ALB C3 C4A COL4A3 COL4A5 CSF1
3 collagen trimer GO:0005581 9.61 C1QC COL4A3 COL4A5
4 azurophil granule lumen GO:0035578 9.58 C3 MPO PRTN3
5 extracellular region GO:0005576 9.53 ALB C1QC C1S C3 C4A C4B
6 blood microparticle GO:0072562 9.5 ALB C1QC C1S C3 C4A C4B
7 collagen type IV trimer GO:0005587 9.37 COL4A3 COL4A5
8 extracellular exosome GO:0070062 10.1 ALB C1QC C1S C3 C4A C4B

Biological processes related to Glomerulonephritis according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.97 C1QC C1S C3 C4A C4B CFH
2 inflammatory response GO:0006954 9.91 C3 C4A C4B CCL2 CD40LG CSF1
3 immune system process GO:0002376 9.91 C1S C3 C4A C4B CD79A CR1
4 cellular protein metabolic process GO:0044267 9.83 ALB C3 C4A CSF1
5 negative regulation of endopeptidase activity GO:0010951 9.78 C3 C4A C4B COL4A3
6 complement activation GO:0006956 9.73 C1QC C1S C3 C4A C4B CFH
7 collagen catabolic process GO:0030574 9.67 COL4A3 COL4A5 PRTN3
8 complement activation, alternative pathway GO:0006957 9.58 C3 CFH CFHR5
9 collagen-activated tyrosine kinase receptor signaling pathway GO:0038063 9.54 COL4A3 COL4A5
10 glomerular basement membrane development GO:0032836 9.51 COL4A3 NPHS1
11 complement activation, classical pathway GO:0006958 9.5 C1QC C1S C3 C4A C4B CFI
12 positive regulation of apoptotic cell clearance GO:2000427 9.46 C3 C4A C4B CCL2
13 regulation of complement activation GO:0030449 9.28 C1QC C1S C3 C4A C4B CFH
14 proteolysis GO:0006508 10 C1QC C1S C3 C4A C4B CFI

Molecular functions related to Glomerulonephritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serine-type endopeptidase activity GO:0004252 9.17 C1QC C1S C3 C4A C4B CFI
2 endopeptidase inhibitor activity GO:0004866 9.13 C3 C4A C4B

Sources for Glomerulonephritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....